Other Clinical Trial - Octaplas Pediatric Plasma Exchange Trial

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

To assess the safety and tolerability of octaplas™ in the pediatric population by monitoring serious adverse drug reactions, adverse drug reactions (ADRs), thrombotic events (TEs), thromboembolic events (TEEs) and by measuring safety laboratory parameters in pediatric patients who require therapeutic plasma exchange.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02007473` - A Prospective Non-interventional Study to Evaluate the Safety of Methylene Blue Plasma	N/A

NCT number	NCT01938378
Study type	Interventional
Source	Octapharma
Contact
Status	Completed
Phase	Phase 4
Start date	April 2015
Completion date	January 27, 2019

Octaplas Pediatric Plasma Exchange Trial — Octaplas

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms